-+ 0.00%
-+ 0.00%
-+ 0.00%

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

Barchart·09/15/2026 08:15:00
Listen to the news

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol

Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.